Druckenmiller Returns to Chinese Tech Stocks; Tepper Doubles Down on Baidu While Trimming Alibaba
nashnova research
Druckenmiller bought back into Chinese tech for the first time in over two years and Tepper nearly doubled his Baidu stake — while gutting Alibaba, JD, and PDD. Wall Street's top macro investors are re-sorting China ADRs along a single line: AI.
Why did Druckenmiller come back after two years?
Duquesne Family Office bought 88,200 Baidu ADRs in Q2, worth roughly $10.1 million.
This is the firm's first position in a U.S.-listed Chinese company since it exited Alibaba entirely in Q4 2023.
This means → Druckenmiller didn't "return to China." He picked one company with a concrete AI pivot and re-entered on that basis alone.
Why does Tepper's book look self-contradictory?
Appaloosa nearly doubled its Baidu stake to about 1.3 million ADRs, valued at roughly $148 million.
In the same quarter, the fund cut 42% of its Alibaba position and completely exited JD.com and PDD Holdings.
In plain terms = at the end of 2024, Tepper was telling everyone to "buy everything China." Now he's kept only the one name with an AI story — the playbook shifted from "buy the basket" to "pick the standout."
Why are institutions singling out Baidu?
Baidu has been investing steadily in AI across three tracks: the Ernie large language model, cloud computing, and autonomous driving.
This reflects a deeper filter: institutions aren't buying "cheap China" — they're buying "does this company have visible AI execution?"
China ADRs without that narrative — Alibaba, JD, PDD — were sold down by the very same funds in the very same quarter.
Can this divergence last?
The current bets are ultimately a wager on AI monetization — whether Baidu's large model and self-driving units can turn into real revenue remains unproven.
This means → if Baidu's AI revenue fails to materialize, these positions could be unwound just as quickly as Alibaba's were two years ago.
Put simply = the big money is in, but it is not conviction — it is a conditional bet.
市场有风险，内容仅供研究参考，不构成投资建议。